The 5-year DFS and OS rates were significantly lower in age<35 than in age≥35 patients. In the Luminal B, HER2-positive, Triple-negative group, the 5-year recurrence risk was higher in age<35 than in age≥35 patients, and age<35 patients' 5-year death risk was higher only in Luminal B, Triple-negative group. Regardless of whether lymph node involved, age<35 patients had a bad prognosis in both DFS and OS. Conclusions: Compared with premenopausal age ≥35 breast cancer, age<35 patients had a worse outcome.
OBJECTIVE: To explore the role of contrast-enhanced ultrasound (CEUS) in the early evaluation of microvacularization in patients with aggressive B-cell lymphoma treated by R-CHOP. MATERIALS AND METHODS: Fifty-two patients with aggressive B-cell lymphoma underwent combined rituximab-CHOP treatment (CHOP: cyclophosphamide, hydroxydaunomycin, vincristine, prednisonetreatment). Before the treatment and after the first two cycles of R-CHOP, CEUS was performed to assess the microvascularization of tumors. In addition, PET/CT examination was also included in this study before and after the treatment. Ideal cut-off value of CEUS parameters was calculated using receiver-operating characteristic (ROC) curve analysis to predict the treatment outcome. The response to treatment, progressionfree survival (PFS) and overall survival (OS) were then compared according to PET/CT and CEUS results. The correlation between CEUS parameters and PET/CT results was investigated based on these analyses. RESULTS: All patients were non-Hodgkin lymphomas (NHL) with CD20 positive. The variations of CEUS parameters (peak intensity and mean intensity) at the mid-term of R-CHOP treatment significantly associated with results of treatment response (P < 0.001), and were also positive correlation with PET/CT results (P = 0.001). The CEUS positive or negative results were determined by cut-off points of peak intensity and mean intensity (4.70 and 4.15dB). The median time of clinical follow-up was 35.4 months. Kaplan-Meier survival analysis demonstrated that PET/CT and CEUS were both good predictors for PFS and OS rate in these patients.
X. Wei et al. / The role of CEUS in early assessment of lymphoma by R-CHOPCONCLUSION: As a microvascular imaging modality, CEUS could be a feasible tool to predict the survival rate of patients with aggressive B-cell lymphoma after R-CHOP treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.